Animas Stock Pumped Up 22% By Takeover Speculation In February – Index
This article was originally published in The Gray Sheet
Executive Summary
Continued strong demand for Animas insulin pumps is fueling forecasts by some investors of a potential merger with Johnson & Johnson
You may also be interested in...
Johnson & Johnson Snags Animas To Advance Artificial Pancreas Design
Johnson & Johnson/LifeScan will acquire long-sought access to the continuous glucose monitoring system (CGMS) market with its $518 mil. purchase of Animas, the firm announced Dec. 16
Johnson & Johnson Snags Animas To Advance Artificial Pancreas Design
Johnson & Johnson/LifeScan will acquire long-sought access to the continuous glucose monitoring system (CGMS) market with its $518 mil. purchase of Animas, the firm announced Dec. 16
ANS Stimulates Wall Street With New Rechargeable IPG, Parkinson’s Trial
Advanced Neuromodulation Systems expects the full roll-out of its Eon rechargeable implantable pulse generator in the second half of the year to help propel a continued rebound of the firm's stock